EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression

Jean-Louis Lacaze iD, Bastien Cabarrou iD, Thibaut Cassou-Mounat iD, Ciprian Chira, Celine Dalmasso iD, Eleonora De Maio iD, Eva Jouve iD, Clément Korenbaum iD, Carole Massabeau iD, Vincent Nicolai, François Poumeaud iD, Gabrielle Selmes iD und 1 weitere

The Oncologist · 07.10.2026 · 31 (11)

DOI: 10.1093/oncolo/oyag413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 19.10.2026. Verfasst von Jean-Louis Lacaze und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Receptors, Estrogen, Receptors, Progesterone. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The management of oligometastatic breast cancer (OMBC) remains controversial, particularly regarding selection for local ablative treatment (LAT). In HR+/HER2− OMBC, where prolonged survival is often the case, improved stratification and characterization of progression may guide treatment. We aimed to define prognostic subsets, assess the contribution of Modern-Imaging-Methods (MIMs; 18F-FDG-PET/CT or WB-MRI) to LAT selection, and describe progression after first-line therapy in these subgroups of patients. Materials and Methods All consecutive patients with HR+/HER2− OMBC treated at our institution between 2012 and 2020 were included. OMBC was defined as ≤5 metastases. Prognostic factors, including biological subtype, anatomical distribution, imaging modality, and LAT, were evaluated for overall and progression-free survival (OS, PFS).

Results

Among 145 patients (median follow-up 82.8 months), median OS and PFS were, respectively, 81.1 and 26.5 months. Luminal-A-like subtypes, absence of liver metastases, and use of MIMs independently predicted better survival. LAT improved PFS (hazard ratio [HR] = 0.52; 95% CI: 0.29-0.91, P = .0233) and showed a trend toward longer OS. In patients staged with MIMs, LAT significantly improved both OS (HR = 0.29; 95% CI: 0.12-0.73, P = .008) and PFS (HR = 0.40; 95% CI: 0.21-0.77, P = .0064). After first-line systemic therapy, only 18% developed polymetastatic progression.

Conclusion

In HR+/HER2− OMBC, 3 actionable considerations emerge: staging must incorporate modern imaging to accurately define metastatic burden; LAT may be considered in selected patients with low-grade disease, absence of liver metastases, and long disease-free interval; in oligoprogression after first-line therapy, LAT should be re-evaluated within a multidisciplinary setting. These data offer pragmatic benchmarks to individualize treatment while awaiting definitive randomized evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBreast NeoplasmsReceptors, EstrogenReceptors, ProgesteroneHumansFemalePrognosisDisease ProgressionMiddle AgedAgedAdultNeoplasm Metastasis

Stichwörter der Autor:innen

breast neoplasmsoligometastasisoligorecurrenceprognosisradiotherapystereotactic

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Department of Medical Oncology, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
  • Biostatistics & Health Data Science Unit, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
  • Department of Radiology, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
  • Department of Radiotherapy, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.
  • Department of Surgery, IUCT-Oncopole, Oncopole Claudius Regaud, Université de Toulouse, Toulouse 31059, France.

ORCID-Profile: Jean-Louis Lacaze, Bastien Cabarrou, Thibaut Cassou-Mounat, Celine Dalmasso, Eleonora De Maio, Eva Jouve, Clément Korenbaum, Carole Massabeau, François Poumeaud, Gabrielle Selmes

Zitieren

APA

Lacaze, J. L., Cabarrou, B., Cassou-Mounat, T., Chira, C., Dalmasso, C., De Maio, E., Jouve, E., Korenbaum, C., Massabeau, C., Nicolai, V., Poumeaud, F., Selmes, G., & Ung, M. (2026). Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag413

Vancouver

Lacaze JL, Cabarrou B, Cassou-Mounat T, Chira C, Dalmasso C, De Maio E, et al. Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag413

BibTeX
@article{Lacaze2026,
  author = {Lacaze, Jean-Louis and Cabarrou, Bastien and Cassou-Mounat, Thibaut and Chira, Ciprian and Dalmasso, Celine and De Maio, Eleonora and Jouve, Eva and Korenbaum, Clément and Massabeau, Carole and Nicolai, Vincent and Poumeaud, François and Selmes, Gabrielle and Ung, Mony},
  title = {Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {11},
  doi = {10.1093/oncolo/oyag413}
}
Kostenlos starten →